Links Home FDA Information

Angiomax This page contains recent news articles, when available, and an overview of Angiomax (bivalirudin)Recent news articles mentioning Angiomax Panacos Reports Fourth Quarter and Full Year 2006 Financial Results  -  21 Feb 2007 Genetic Engineering News (press release), Dr. Lategan was instrumental in the regulatory approvals of several drugs, including TRACLEER, ZAVESCA, and ANGIOMAX and was previously Vice President, Jeffrey Mazzella: Congressional solution for patent law’s ...  -  Feb 13, 2007 Examiner.com Take, for example, the drug Angiomax, marketed by The Medicines Company. According to reports, in 2001 the company filed its application for patent-term Medicines Swings to 4Q Profit  -  Feb 14, 2007 Houston Chronicle, The company cited sales of its anticoagulant Angiomax as a key reason for the boost in revenue. For the full year, the company earned $63.7 million, UPDATE 2-Medicines Co. halts offering pending patent extension  -  Jan 24, 2007 Reuters ..."We continue to believe that the likelihood of patent extension for Angiomax is low," UBS analyst Maged Shenouda said in a research note. The Medicines Company Determines Not to Proceed with Proposed Offering  -  Jan 24, 2007 Oxfordshire Bioscience Network (press release), The Company markets Angiomax(R) (bivalirudin) in the US and other countries for use in patients undergoing coronary angioplasty, a procedure to clear Medicines Co. Cancels Stock Offering  -  Jan 24, 2007 Forbes, Angiomax prevents blood clots and is used during coronary angioplasty, a procedure where a balloon catheter is inflated inside a heart artery to unblock it. Medicines Co (MDCO) Cancels Stock Offering Related to Pending ...  -  Jan 24, 2007 StreetInsider.com (subscription), ...occur in the near term with respect to the Company's application for term extension for the principal patent covering the Company's product Angiomax. The Medicines Company Supports Landmark Patient Observational ...  -  Feb 20, 2007 Medical News Today (press release), The Company markets Angiomax(R) (bivalirudin) in the US and other countries for use in patients undergoing coronary angioplasty, a procedure to clear UPDATE 1-Medicines Co. not to proceed with stock offering  -  Jan 24, 2007 Reuters ...a proposed stock offering as it expects some "administrative activity" on its bid to extend a patent on its flagship drug Angiomax, a blood thinner. Medicines Co. says not to proceed with stock offering  -  Jan 24, 2007 Reuters ...with its proposed stock offering as it expects some "administrative activity" related to extension of a patent covering its blood thinner drug Angiomax. Medicines Company Cancels Secondary Offering  -  Jan 24, 2007 Business New Jersey (subscription), ...its application for an extension of its patent for Angiomax (bivalirudin), a drug used during angioplasty procedures to prevent blood clotting. Panacos Appoints Dr. Tom Lategan, Vice President of Regulatory Affairs  -  Feb 14, 2007 Business Wire (press release), TRACLEER and ZAVESCA are registered trademarks of Actelion Pharmaceuticals Ltd. ANGIOMAX is a registered trademark of The Medicines Company Inc. The Medicines Company Reports Fourth Quarter and Full Year 2006 ...  -  Feb 14, 2007 PharmaLive.com (press release), ..."We exceeded the sales goal for Angiomax, we completed the Phase III safety trials of Cleviprex(TM) (clevidipine), our novel blood pressure control agent, Analysis: 'New' heparin stops clots  -  Feb 9, 2007 Science Daily (press release) Angiomax reduces bleeding in heart cases (November 22, 2006) -- The anti-clotting agent billiard (Anima) reduces the rate of serious bleeding incidents when Premarket Movers: Sun Micro Shines  -  Jan 24, 2007 Forbes, ...that "some administrative activity" could soon occur in regard to its application for an extension for the main patent covering its Angiomax drug. Other uses for Angiomax [MedMaster Patient Drug Information database] Before taking rosiglitazone, tell your doctor and pharmacist if you are allergic to rosiglitazone or any other medications. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: candesartan (Atacand), felodipine (Lexxel, Plendil), gemfibrozil (Lopid), insulin and other medications for diabetes,montelukast (Singulair), phenobarbital, rifampin (Rifadin, Rimactane in Rifamate), trimethoprim (in Bactrim, in Septra, others), and zafirlukast (Accolate). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.. tell your doctor if you have or have ever had any type of heart disease including heart failure or a heart attack; high blood pressure; high cholesterol or fats in the blood; swelling of the hands, arms, feet, ankles, or lower legs; diabetic eye disease such as macular edema (swelling of the back of the eye); type 1 diabetes; diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated in a diabetic patient); or liver disease. Also tell your doctor if you have ever taken troglitazone (Rezulin, no longer available in the United States), especially if you stopped taking it because you experienced side effects. tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking rosiglitazone, call your doctor. Do not breastfeed while you are taking rosiglitazone. if you have not yet experienced menopause (change of life; end of monthly periods) you should know that rosiglitazone may increase the chance that you will become pregnant even if you do not have regular monthly periods or you have a condition that prevents you from ovulating (releasing an egg from the ovaries). Talk to your doctor about methods of birth control that will work for you. plan to follow the exercise program recommended by your doctor. Regular exercise will help to control your diabetes. talk to your doctor about how often you should test your blood sugar during your treatment with rosiglitazone. Follow these instructions carefully.